Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

25.45
+0.70002.83%
Post-market: 25.450.00000.00%16:59 EDT
Volume:296.73K
Turnover:7.49M
Market Cap:699.90M
PE:-9.47
High:25.77
Open:25.17
Low:24.78
Close:24.75
Loading ...

Xilio Therapeutics Q4 2024 GAAP EPS $(0.20) Beats $(0.21) Estimate, Xilio Anticipates That Its Cash And Cash Equivalents Of $55.3M As Of December 31, 2024, Together With The $52M Upfront Payments Received From AbbVie Is Expected To Provide Cash Runway Into Q1 Of 2026

Benzinga
·
11 Mar

Xilio Therapeutics reports Q4 EPS (20c) vs (64c) last year

TIPRANKS
·
11 Mar

Press Release: Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Dow Jones
·
11 Mar

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

GlobeNewswire
·
11 Mar

Werewolf Therapeutics Q4 2024 GAAP EPS $(0.46) Misses $(0.42) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Were $111M, Expected To Provide Cash Runway Into Q2 Of 2026

Benzinga
·
11 Mar

Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
11 Mar

Rapport Therapeutics Q4 2024 GAAP EPS $(0.57) Beats $(0.62) Estimate, Ended the year with $305.3M in cash, cash equivalents, and short-term investments, which is expected to fund operations through the end of 2026

Benzinga
·
11 Mar

Bicycle Therapeutics Price Target Maintained With a $30.00/Share by Needham

Dow Jones
·
11 Mar

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

Business Wire
·
11 Mar

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

GlobeNewswire
·
11 Mar

RBC Raises Price Target on Design Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
11 Mar

Tenaya Therapeutics price target lowered to $5 from $18 at H.C. Wainwright

TIPRANKS
·
11 Mar

Checkpoint Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
11 Mar

Protara Therapeutics initiated with an Outperform at LifeSci Capital

TIPRANKS
·
11 Mar

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

StockStory
·
11 Mar

Optimistic Buy Rating for Aquestive Therapeutics Driven by Anaphylm NDA Submission and Strong Financial Position

TIPRANKS
·
11 Mar